Tuesday, December 13, 2011
The epidemic of medical child abuse - and what can be done about it
(NaturalNews) The primary purpose of this article is to encourage a stronger commitment from doctors and parents to consider using safer medical care for infants and children FIRST before resorting to more dangerous treatments. One would hope and assume that doctors and parents would have a natural inclination to make the safety of these young human souls a significant and sincere priority, but sadly, the power and propaganda of Big Pharma has inappropriately turned this equation around and made it seem that doctors and parents are putting their children at risk if they don't prescribe powerful drugs first. This writer personally disagrees with this assumption and sincerely hopes thatpeopleconsider this health issue to be of primary importance today.
Wednesday, December 7, 2011
HHS releases new plan to prevent and treat viral hepatitis
(NaturalNews) Viral hepatitis remains a public health challenge in the United States. Approximately 3.5-5.3 million persons are living with the condition, and millions more are at risk for infection. Hepatitis, which is largely preventable, is the leading cause of liver cancer. Without appropriate care, 1 in 4 persons with chronic hepatitis will develop liver cirrhosis or liver cancer.
In January 2010, the Institute of Medicine (IOM) released a report on hepatitis, explaining the barriers to hepatitis prevention and treatment. In response to this, The U.S. Department of Health and Human Services (HHS) just released the Viral Hepatitis Action Plan --Combating the Silent Epidemic: US Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. The Plan is meant to result in:
- more people being aware that they have the condition
- a reduction in new cases(NaturalNews) Viral hepatitis remains a public health challenge in the United States. Approximately 3.5-5.3 million persons are living with the condition, and millions more are at risk for infection. Hepatitis, which is largely preventable, is the leading cause of liver cancer. Without appropriate care, 1 in 4 persons with chronic hepatitis will develop liver cirrhosis or liver cancer.
In January 2010, the Institute of Medicine (IOM) released a report on hepatitis, explaining the barriers to hepatitis prevention and treatment. In response to this, The U.S. Department of Health and Human Services (HHS) just released the Viral Hepatitis Action Plan --Combating the Silent Epidemic: US Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. The Plan is meant to result in:
- more people being aware that they have the condition
- a reduction in new cases
a complete elimination of mother to child transmission of Hepatitis B
Although viral hepatitis is a leading cause of infectious death in the U.S., many people are unaware they have the condition because often time they don't feel the symptoms, or the symptoms are there, but just feel like the flu.
Here's a quick overview of viral hepatitis:
Hepatitis A - found in the feces of infected persons. Hepatitis A spreads from one person to another by putting something in the mouth that has been contaminated with the stool of a person with hepatitis A. This can happen when people do not wash their hands after using the toilet and then touch other people's food. Typically, milder symptoms than hepatitis Bor C. Illness from hepatitis A is usually brief, and infection with the virus does not lead to chronic liver disease or liver cancer.
Hepatitis B - found in blood and certain body fluids of infected persons. Hepatitis B spreads when a person who is not immune comes in contact with blood or body fluid from an infected person. Hepatitis B is spread by having sex with an infected person without a condom, sharing needles during injected drug use, needle sticks or sharps, exposures in a health care setting, or from an infected mother to her baby during vaginal birth. Exposure to blood in any situation can be a risk for transmission. There are usually no symptoms until there are serious liver complications. When symptoms do appear, they may include high fever, jaundice and abdominal pain chronic hepatitis B can lead to cirrhosis and/or liver cancer.
Hepatitis C - also found in blood and certain body fluids of infected persons. Hepatitis C spreads when a person who is not immune comes in contact with blood or body fluids from an infected person. Hepatitis C is spread through sharing needles during injecteddruguse, needle sticks or sharps, exposures in ahealthcare setting, through organ transplants that have not been screened, or less commonly from an infected mother to her baby during vaginal birth. It is possible to gethepatitis Cfrom sex, but it is uncommon. Infection with the hepatitis Cvirusis the number one reason for liver transplant in the U.S. Unlike hepatitis A and B, there is no vaccine to prevent hepatitis C.
There is a simple blood test to check for the Hepatitis virus.
Hopefully, with the guidance of this plan and the collaboration of policy figures, stake holders, and health care practitioners we can reduce the transmission of this silentepidemic.
In January 2010, the Institute of Medicine (IOM) released a report on hepatitis, explaining the barriers to hepatitis prevention and treatment. In response to this, The U.S. Department of Health and Human Services (HHS) just released the Viral Hepatitis Action Plan --Combating the Silent Epidemic: US Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. The Plan is meant to result in:
- more people being aware that they have the condition
- a reduction in new cases(NaturalNews) Viral hepatitis remains a public health challenge in the United States. Approximately 3.5-5.3 million persons are living with the condition, and millions more are at risk for infection. Hepatitis, which is largely preventable, is the leading cause of liver cancer. Without appropriate care, 1 in 4 persons with chronic hepatitis will develop liver cirrhosis or liver cancer.
In January 2010, the Institute of Medicine (IOM) released a report on hepatitis, explaining the barriers to hepatitis prevention and treatment. In response to this, The U.S. Department of Health and Human Services (HHS) just released the Viral Hepatitis Action Plan --Combating the Silent Epidemic: US Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. The Plan is meant to result in:
- more people being aware that they have the condition
- a reduction in new cases
a complete elimination of mother to child transmission of Hepatitis B
Although viral hepatitis is a leading cause of infectious death in the U.S., many people are unaware they have the condition because often time they don't feel the symptoms, or the symptoms are there, but just feel like the flu.
Here's a quick overview of viral hepatitis:
Hepatitis A - found in the feces of infected persons. Hepatitis A spreads from one person to another by putting something in the mouth that has been contaminated with the stool of a person with hepatitis A. This can happen when people do not wash their hands after using the toilet and then touch other people's food. Typically, milder symptoms than hepatitis Bor C. Illness from hepatitis A is usually brief, and infection with the virus does not lead to chronic liver disease or liver cancer.
Hepatitis B - found in blood and certain body fluids of infected persons. Hepatitis B spreads when a person who is not immune comes in contact with blood or body fluid from an infected person. Hepatitis B is spread by having sex with an infected person without a condom, sharing needles during injected drug use, needle sticks or sharps, exposures in a health care setting, or from an infected mother to her baby during vaginal birth. Exposure to blood in any situation can be a risk for transmission. There are usually no symptoms until there are serious liver complications. When symptoms do appear, they may include high fever, jaundice and abdominal pain chronic hepatitis B can lead to cirrhosis and/or liver cancer.
Hepatitis C - also found in blood and certain body fluids of infected persons. Hepatitis C spreads when a person who is not immune comes in contact with blood or body fluids from an infected person. Hepatitis C is spread through sharing needles during injecteddruguse, needle sticks or sharps, exposures in ahealthcare setting, through organ transplants that have not been screened, or less commonly from an infected mother to her baby during vaginal birth. It is possible to gethepatitis Cfrom sex, but it is uncommon. Infection with the hepatitis Cvirusis the number one reason for liver transplant in the U.S. Unlike hepatitis A and B, there is no vaccine to prevent hepatitis C.
There is a simple blood test to check for the Hepatitis virus.
Hopefully, with the guidance of this plan and the collaboration of policy figures, stake holders, and health care practitioners we can reduce the transmission of this silentepidemic.
Natural source of omega-3 Fish Oil 1000mg
Each softgel capsule contains
Fish oil - natural (1000 mg) 1g
400 Capsules
AUST L 121387
Healthy Care regularly tests their Fish oil for mercury
Fish oil is extracted from cold water fish and is a natural source of marine omega-3 fatty acids. Fish Oil contains the omega-3 fatty acids EPA and DHA, and can be taken as a dietary supplement.
Fish oil provides an anti-inflammatory action within the body which may reduce inflammation and joint swelling associated with arthritis. Omega-3 fatty acids are also important for cardiovascular health.
In addition to these benefits, Healthy Care Fish Oil 1000 is a beneficial supplement to take if you can't manage the recommended 2-3 serves of fish a week. It is also high in DHA which is necessary for the normal function of the eye, brain and nervous system.
To ensure you can take Healthy Care Fish Oil 1000 with confidence, Healthy Care regularly tests its fish oil for mercury and only uses high quality fish oil without added artificial surfactants to disguise fishy odors.
Benefits:
Helps relieve symptoms of :
-- Arthritis
-- Swollen Joints
-- Dermatitis
-- Psoriasis
-- Inflammatory Disorders
Helps relieve symptoms of :
-- Arthritis
-- Swollen Joints
-- Dermatitis
-- Psoriasis
-- Inflammatory Disorders
Maintains normal healthy :
-- Cardiovascular system
-- Eye Function
-- Brain function
-- Cholesterol level
-- Nervous System
Active Ingredient:-- Cardiovascular system
-- Eye Function
-- Brain function
-- Cholesterol level
-- Nervous System
Fish Oil-Natural (Salmon Oil) | 750mg |
Natural Vitamin E - 10 IU (Equiv. d-alpha-Tocopherol 6.71mg) | |
Natural Fish Oil 1000mg contains: | |
Omega-3 Marine Triglycerides 300mg as: | |
Eicosapentaenoic Acid (EPA) | 180mg |
Docosahexaenoic Acid (DHA) | 120mg |
(Equiv. Vitamin A 25 IU) | |
[Equiv. Vitamin D3 2.5 IU (Cholecalciferol 62.5mg)] |
Tuesday, December 6, 2011
Diabetes Medical Treatment
Diabetes Medical Treatment
The treatment of diabetes is highly individualized, depending on the type of diabetes, whether the patient has other active medical problems, whether the patient has complications of diabetes, and age and general health of the patient at time of diagnosis.
- A health care professional will set goals for lifestyle changes, blood sugar control, and treatment.
- Together, the patient and the health care professional will formulate a plan to help meet those goals.
- When the patient is first diagnosed with diabetes, the diabetes care team will spend a lot of time with the patient, teaching them about their condition, treatment, and everything they need to know to care for themselves on a daily basis.
- The diabetes care team includes the health care professional and his or her staff. It may include specialists in foot care, neurology, kidney diseases, and eye diseases. A professional dietitian and a diabetes educator also may be part of the team.
The health care team will see the patient at appropriate intervals to monitor their progress and evaluate goals.
Treatment of diabetes almost always involves the daily injection of insulin, usually a combination of short-acting insulin (for example, lispro [Humalog] or aspart [NovoLog]) and a longer acting insulin (for example, NPH, Lente, glargine [Lantus], detemir [Levemir]).
- Insulin must be given as an injection just under the skin. If taken by mouth, insulin would be destroyed in the stomach before it could get into the blood where it is needed.
- Most people with type 1 diabetes give these injections to themselves. Even if someone else usually gives the patient injections, it is important that the patient knows how to do it in case the other person is unavailable.
- A trained professional will show the patient how to store and inject the insulin. Usually this is a nurse who works with the health care professional or a diabetes educator.
- Insulin is usually given in two or three injections per day, generally around mealtimes. Dosage is individualized and is tailored to the patient's specific needs by the health care professional. Longer acting insulins are typically administered one or two times per day.
- Some people have their insulin administered by continuous infusion pumps to provide adequate blood glucose control. Supplemental mealtime insulin is programmed into the pump by the individual as recommended by his or her health care professionals.
- It is very important to eat after the taking insulin, as the insulin will lower blood sugar regardless of whether the person has eaten. If insulin is taken without eating, the result may be hypoglycemia. This is called an insulin reaction.
- There is an adjustment period while the patient learns how insulin affects them, and how to time meals and exercise with insulin injections to keep blood sugar levels as even as possible.
- Keeping accurate records of blood sugar levels and insulin dosages is crucial for the patient's diabetes management.
- Eating a consistent, healthy diet appropriate for the patient's size and weight is essential in controlling blood sugar level.
Depending on how elevated the patient's blood sugar and glycosylated hemoglobin (HbA1c) are at the time of diagnosis, they may be given a chance to lower blood sugar levels through lifestyle changes, without medication.
- The best way to do this is to lose weight if the patient is obese, and begin an exercise program.
- This will generally be tried for 3 to 6 months, then blood sugar and glycosylated hemoglobin will be rechecked. If they remain high, the patient will be started on an oral medication, usually a sulfonylurea or biguanide (metformin [Glucophage]), to help control blood sugar levels.
- Even if the patient is on medication, it is still important to eat a healthy diet, lose weight if they are overweight, and engage in moderate physical activity as often as possible.
- The health care professional will initially monitor the patient's progress on medication very carefully. It is important to receive just the right dose of the right medication, to regulate blood sugar levels in the recommended range with the fewest side effects.
- The doctor may decide to combine two types of medications to achieve blood sugar levels control.
- Gradually, even people with type 2 diabetes may require insulin injections to control their blood sugar levels.
- It is becoming more common for people with type 2 diabetes to take a combination of oral medication and insulin injections to control blood sugar levels.
Standards of Medical Care for Diabetes
Standards of Medical Care for Patients With Diabetes Mellitus
- American Diabetes Association
Diabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. Diabetes care is complex and requires that many issues, beyond glycemic control, be addressed. A large body of evidence exists that supports a range of interventions to improve diabetes outcomes.
These standards of care are intended to provide clinicians, patients, researchers, payers, and other interested persons with the components of diabetes care, treatment goals, and tools to evaluate the quality of care. While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed. For more detailed information, refer to Skyler (Ed.): Medical Management of Type 1 Diabetes (1) and Zimmerman (Ed.): Medical Management of Type 2 Diabetes (2).
The recommendations included are diagnostic and therapeutic actions that are known or believed to favorably affect health outcomes of patients with diabetes. A grading system (Table 1), developed by the Association and modeled after existing methods, was utilized to clarify and codify the evidence that forms the basis for the recommendations
CLASSIFICATION, DIAGNOSIS, AND SCREENING
ClassificationIn 1997, the American Diabetes Association issued new diagnostic and classification criteria (3).
The classification of diabetes mellitus includes four clinical classes
- Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency)
- Type 2 diabetes (Results from a progressive insulin secretory defect on the background of insulin resistance)
- Other specific types of diabetes (due to other causes, e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas, drug or chemical induced)
- Gestational diabetes mellitus (GDM) (diagnosed during pregnancy)
Criteria for the diagnosis of diabetes in nonpregnant adults are shown in Table 2. Three ways to diagnosis diabetes are available and each must be confirmed on a subsequent day. Because of ease of use, acceptability to patients and lower cost, the fasting plasma glucose (FPG) is the preferred test.
Hyperglycemia not sufficient to meet the diagnostic criteria for diabetes is categorized as either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), depending on whether it is identified through a FPG or an oral glucose tolerance test (OGTT): IFG = FPG ≥110 mg/dl (6.1 mmol/l) and <126 mg/dl (7.0 mmol/l) Or FPG 110 mg/dl (6.1 mmol/l) to 125 mg/dl (6.9 mmol/l) IGT = 2-h PG ≥140 mg/dl (7.8 mmol/l) and <200 mg/dl (11.1 mmol/l) Or 2-h PG 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l)
ScreeningGenerally, people with type 1 diabetes present with acute symptoms of diabetes and markedly elevated blood glucose levels. Type 2 diabetes is frequently not diagnosed until complications appear, and approximately one-third of all people with diabetes may be undiagnosed. Although the burden of diabetes is well known, the natural history is well characterized, and there is good evidence for benefit from treating cases diagnosed through usual clinical care, there are no randomized trials demonstrating the benefits of early diagnosis through screening of asymptomatic individuals (8). Nevertheless, there is sufficient indirect evidence to justify opportunistic screening in a clinical setting of individuals at high risk. Criteria for testing for diabetes in asymptomatic, undiagnosed adults are listed in Table 3. The recommended screening test for nonpregnant adults is the FPG.
Detection and diagnosis of GDMRisk assessment for GDM should be undertaken at the first prenatal visit. Women with clinical characteristics consistent with a high risk for GDM (those with marked obesity, personal history of GDM, glycosuria, or a strong family history of diabetes) should undergo glucose testing as soon as possible (10). A fasting plasma glucose ≥126 mg/dl or a casual plasma glucose ≥200 mg/dl meets the threshold for the diagnosis of diabetes, if confirmed on a subsequent day. High-risk women not found to have GDM at the initial screening and average-risk women should be tested between 24 and 28 weeks of gestation. Testing should follow one of two approaches:
- One-step approach: perform a diagnostic OGTT.
- Two-step approach: perform an initial screening by measuring the plasma or serum glucose concentration 1 h after a 50-g oral glucose load (glucose challenge test [GCT]) and perform a diagnostic OGTT on that subset of women exceeding the glucose threshold value on the GCT. When the two-step approach is employed, a glucose threshold value ≥140 mg/dl identifies ∼80% of women with GDM, and the yield is further increased to 90% by using a cutoff of ≥130 mg/dl.
Diagnostic criteria for the 100-g OGTT is as follows: ≥95 mg/dl fasting; ≥180 mg/dl at 1 h; ≥155 mg/dl at 2 h; ≥140 mg/dl at 3 h. Two or more of the plasma glucose values must be met or exceeded for a positive diagnosis. The test should be done in the morning after an overnight fast of 8–14 h. The diagnosis can be made using a 75-g glucose load, but that test is not as well validated for detection of at-risk infants or mothers as the 100-g OGTT.
Low risk status requires no glucose testing, but this category is limited to those women meeting all of the following characteristics:
- Age <25 years
- Weight normal before pregnancy
- Member of an ethnic group with a low prevalence of GDM
- No known diabetes in first-degree relatives
- No history of abnormal glucose tolerance
- No history of poor obstetric outcome
Recommendations
A-Level evidence
- In those with IFG/IGT, lifestyle modification should be considered.
- The FPG is the preferred test to screen for and diagnose diabetes.
- Screen for diabetes in high-risk, asymptomatic, undiagnosed adults and children within the health care setting.
- Screen for diabetes in pregnancy using risk factor analysis and screening tests as noted.